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Abstract 
Background and purpose 
Cone beam CT (CBCT) is used to improve accuracy of radical radiotherapy by adjusting 
treatment to the observed imaging changes. To ensure appropriate adjustment, image 
interpretation should precede any changes to treatment delivery. This study provides the 
methodology for image interpretation and the frequency and evolution of the changes in 
patients undergoing radical radiotherapy for localised and locally advanced non-small cell 
lung cancer (NSCLC).  
Patients and methods 
From December 2012 to December 2014, 250 patients with localised and locally advanced 
NSCLC had 2462 chest CBCT scans during the course of fractionated radical radiotherapy 
(RT) (3 – 5 daily CBCTs in the first week followed by at least weekly imaging, mean 9.5 per 
patient, range 1-21).  All CBCT images were reviewed describing changes and their evolution 
using diagnostic imaging definitions and validated by an independent chest radiologist. 
Results  
During radical RT for NSCLC 328 imaging changes were identified on CBCT in 180 (72%) 
patients; 104 (32%) had reduction and 41 (13%) increase in tumour size; 48 (15%) had 
changes in consolidations contiguous to the primary lesion, 26 (8%) non-contiguous 
consolidations, 43 (13%) changes in tumour cavitation, 36 (11%) pleural effusion and 30 
(9%) changes in atelectasis.  
In 105 patients imaging changes were noted in continuity with the treated tumour of which 
only 41 (39%) represented tumour enlargement; others included new or enlarging adjacent 
consolidation (34%), and new or enlarging atelectasis (19%). The changes evolved during 
treatment. 
Conclusion 
Imaging changes on CBCT include real and apparent changes in tumour size and 
parenchymal changes which evolve during treatment. Correct image interpretation, 
particularly when occurring adjacent to the tumour, is essential prior to adjustment to 
treatment delivery.  
 
 
 
 
Introduction 
High dose fractionated external beam radiotherapy with or without chemotherapy remains 
the mainstay of radical treatment of localised and locally advanced non-small cell lung 
cancer (NSCLC) not amenable to surgical excision 1. 
Successful outcome demands accurate tumour localisation and precise delivery of 
treatment. These are dependent on the quality of imaging determined both by technical 
and operator related factors.  In the treatment of lung cancer the imaging modality of 
choice to define the target and critical normal structures currently remains CT scanning.  
While the technical aspects of CT imaging continue to improve to allow better visualisation 
of thoracic structures, operator dependent image interpretation has been subject to less 
academic scrutiny, yet this is likely to be an important determinant of accuracy of 
radiotherapy delivery. 
The principal focus of the accuracy and reliability of image interpretation which defines the 
target for treatment has been on pre-treatment imaging where target outlining is an 
integral component of the treatment planning process. An increasingly important aspect of 
radiotherapy imaging which guides the quality of radiotherapy delivery is image guidance 
during treatment currently using cone beam CT (CBCT) mounted on the linear accelerator 2. 
As with pre-treatment CT, the accuracy of treatment relies on adjusting radiotherapy 
delivery to information obtained from the CBCT image and this demands not only high 
quality imaging but also correct and reliable image interpretation. This expertise rests either 
with the radiation oncologist or in many centres with the radiation therapist/technologist. 
CBCT image interpretation has been entirely in the hands of the treating profession and not 
subject to assessment and validation by imaging experts (radiologists). It is therefore a 
largely non-validated skill which is open to significant interobserver variation and potential 
incorrect interpretation of the images. To ensure the image interpretation complies with 
validated imaging criteria the study was designed and conducted together with an expert 
thoracic radiologist. 
The study examined in detail over 2000 CBCT images in 250 patients undergoing radical 
radiotherapy for locally advanced NSCLC describing imaging changes and their evolution 
using validated imaging definitions and assessed and quality assured by an expert thoracic 
radiologist. This should provide the basis for accurate and reliable interpretation of CBCT 
images during treatment to ensure appropriate adjustment of treatment to enable optimum 
treatment outcome both in terms of best tumour control and minimal treatment related 
toxicity. 
 
 
Patients and methods 
Study population 
Table 1 
Patient & disease characteristics of a cohort of 250 patients with NSCLC treated with radical 
radiotherapy 
Characteristic Number of pts. % 
Gender 250 100% 
F 115 46% 
M 135 54% 
WHO performance status (PS) 
0 58 23% 
1 90 36% 
2 81 32% 
3 9 4% 
NA 12 5% 
COPD comorbidity 
  yes 65 26%
no  185 74% 
Histology 
  adenocarcinoma 86 34%
squamous cell carcinoma 119 48% 
NSCLC NOS 24 10% 
large cell carcinoma 2 1% 
adenosquamous carcinoma 3 1% 
carcinosarcoma 1 0% 
not histologically verified 15 6% 
AJCC stage 
  IA 10 4%
IB 25 10% 
IIA 14 6% 
IIB 24 10% 
IIIA 120 48% 
IIIB 47 19% 
IV 10 4% 
Chemotherapy 
  concurrent chemoradiotherapy 51 20%
sequential chemoradiotherapy 107 43% 
TKI 1 0% 
RT dose fractionation 
  50 – 55 in 20 fractions 242 97%
58 – 60Gy in 20 – 30 fractions 8 3% 
   
The study was a structured review of all available diagnostic, planning, cone beam and post-
treatment CT scans in a cohort of patients undergoing conventional fractionated radical 
external beam radiotherapy (Table 1) for histologically verified NSCLC (with or without 
neoadjuvant & concomitant chemotherapy – Table 1) between 31/12/2012 and 30/12/2014 
with CBCTs obtained in the two calendar years.  All patients had an identifiable tumour on 
CT imaging. Patients undergoing SABR and palliative radiotherapy were excluded from the 
analysis as were patients without an identifiable lung parenchymal tumour (adjuvant 
radiotherapy for microscopic residual disease after surgery), and those who received 
previous thoracic or adjacent radiotherapy (e.g. for breast cancer). 
Imaging 
All patients had planning CT scan with Philips Brilliance CT scanner (Philips N.V., Eindhoven, 
NL). On treatment cone beam CT scans were performed using Varian Truebeam and Varian 
C-series Linac with kV X-ray source OBI (Varian Medical Systems, Palo Alto, California, USA). 
The general policy was to perform 3 – 5 daily CBCTs in the first week followed by at least 
weekly imaging (more when changes were detected requiring potential treatment 
adjustment) with a mean of 9.5 per patient (range 1-21).  Following radiotherapy diagnostic 
CT was carried out 1 – 6 months after completion of treatment with a median of 73 days 
(patients usually have imaging 3 months after treatment but some had it earlier due to 
symptoms or had it at their local hospital first).  
All images were scored and reviewed by one IGRT experienced specialist clinical oncologist 
(EC) with contentious cases reviewed by a thoracic radiologist (JC) or another clinical 
oncologist (MB). The imaging from a randomly selected 10% of the patients was reviewed 
by an expert thoracic radiologist (JC). 
 
Imaging abnormalities 
Imaging abnormalities on planning CT and on CBCT during RT were identified and recorded 
using standard imaging terminology 3. Changes were reported in comparison to planning CT 
and the previous CBCT.  Due to the limited resolution of CBCT images only changes ≥ 3 mm 
were considered significant. Examples are shown in Figure 1.  
Figure 1 
Examples of imaging changes during radical radiotherapy for NSCLC. Planning CT images are shown 
on the left and cone beam CT scan images on the right. 
A tumour enlargement; B reduction in tumour size; C new contiguous consolidation; D cavitation; E 
contralateral pleural effusion; F atelectasis. 
 
 
Tumour enlargement (or progression) was defined as concentric (involving more than 50% 
of the margin) increase of ≥ 3 mm of either maximum diameter or perpendicular maximum 
diameter of the primary tumour.  Similarly tumour reduction (or regression) was defined as 
a decrease in size ≥ 3 mm of maximum or perpendicular maximum diameter of the primary 
tumour. 
Consolidation (or infiltrative change) was classified as contiguous and non-contiguous. 
Contiguous consolidation was defined as increase in pulmonary parenchymal attenuation, 
generally homogeneous, that obscures the margins of vessels and airway walls of at least 3 
mm, not considered to be tumour or atelectasis, contiguous with the tumour, or a 
nonconcentric increase in size of the tumour at least 3 mm affecting less than 50% of the 
tumour margin. 
Non-contiguous consolidation was defined as increased parenchymal attenuation of at least 
3 mm not considered to be tumour or atelectasis contiguous with the tumour. 
Cavitation was defined as a gas-filled space seen as a lucency or low-attenuation area within 
the tumour of at least 3mm. 
Pleural effusion was defined as the presence of at least 3mm of fluid-like density between 
lung and posterior chest wall (on a supine CT scan). 
Atelectasis had the characteristics of consolidation with distinguishing anatomical features 
often associated with abnormal displacement of fissures, bronchi, vessels, diaphragm, heart, 
or mediastinum. 
Quality assurance 
Series of planning, cone beam and post treatment scans from 10% of randomly selected 
patients (25) were reviewed by an experienced thoracic radiologist (JC).  Complete 
concordance was noted in 10 patients. In the remaining 15 patients, 23 out of 30 changes  
were agreed and 7 were amended (4 were added). The overall error rate was < 10% and 
mostly related to lung changes not adjacent to the tumour. Following the review of cases 
the whole image dataset was reviewed with minor amendment and this data is presented. 
Statistical analysis  
SPSS version 21.0, (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. χ2 test and 
Spearman’s rank correlation coefficients were used to assess correlations between imaging 
changes and patient, tumour and treatment characteristics .  
 
 
 
Results 
Patients 
Over a 2 year period (31/12/2012 to 30/12/2014) 430 patients with NSCLC had chest CBCT 
scans during the course of RT. Two hundred and fifty met the inclusion criteria. The patient 
and disease characteristics are shown in Table 1. The majority (67%) had stage III disease; 51 
(20%) received concurrent chemo-radiotherapy and 107 (43%) sequential chemoradiation. 
The majority of patients (241 - 96%) received a dose of 50-55Gy in 20 fractions. 
Most patients completed the full course of treatment. The treatment was discontinued 
early in 8 patients due to treatment related toxicity (2), disease progression (2), increased 
dyspnoea (1) and other reasons (3). 
The majority of patients (170) had a 3D planning scan; 80 had a 4D planning CT scan. Overall 
2378 3D CBCT scans were reviewed (mean 9.5 per patient); 50 patients had 4DCBCT for a 
total number of 84 scans (1-3 per patient). If two CBCT (due to beam repositioning) were 
performed on the same day only the original image was analysed and reported. 
 
Planning CT scan  
On the planning CT scan 363 abnormalities were noted in 212 patients. Contiguous 
consolidation was noted in 125 and non-contiguous in 118 patients; 40 patients had tumour 
cavitation, 32 effusion and 48 atelectasis; 106 patients had one, 67 two, 33 three and 6 four 
abnormalities. 38 patients had no abnormalities on planning CT (Appendix, Table I). 
 
On treatment cone beam CT (CBCT) scan  
Out of 250 patients 180 (72%) had at least one change on CBCT during radiotherapy 
compared to the planning CT scan. This included both new abnormalities and a change in 
size of an existing abnormality (≥ 3mm). Overall 328 changes were identified: 145 were 
alterations in the size of the primary lesion (104 reductions and 41 enlargements) and 183 
were changes not directly involving the tumour mass. Of these 60 were new (not seen on 
planning CT) and 123 were changes of previously identified abnormalities.  
Contiguous consolidation was seen in 48 patients (14 new, 30 increases and 4 reductions of 
pre-existing contiguous consolidation) and non-contiguous consolidations in 26 (5 new, 19 
increases and 2 reductions of pre-existing). Cavitation was noted in 43 patients (14 new, 9 
increases, 20 reductions or disappearance/resolution of pre-existing cavities), pleural 
effusion in 36 (21 new, 10 increases, 5 reductions) and atelectasis in 30 patients (6 new, 14 
increases and 10 reductions). Seventy patients had no changes during RT, 79 had one 
change, 66 had two, 24 three, 10 four and 1 patient had five changes (Table 2). 
Table 2 
Imaging changes on CBCT (250 patients; 328 changes) during radical radiotherapy for NSCLC 
change in tumour size Number of 
changes 
% changes % patients 
enlargement 41 13%  
reduction 104 32%  
Total 145 44% 58% 
 
contiguous consolidation 
new  14 4%  
pre-existing increased 30 9%  
pre-existing decreased 4 1%  
Total 48 15% 19% 
 
non-contiguous consolidation 
 
new  5 2%  
pre-existing increased 19 6%  
pre-existing decreased 2 1%  
Total 26 8% 10% 
 
cavitation 
 
new  14 4%  
pre-existing increased 9 3%  
pre-existing decreased 20 6%  
Total 43 13% 17% 
 
pleural effusion 
 
new  21 6%  
pre-existing increased 10 3%  
pre-existing decreased 5 2%  
Total 36 11% 14% 
 
atelectasis 
 
new  6 2%  
pre-existing increased 14 4%  
pre-existing decreased 10 3%  
Total 30 9% 12% 
 
 
Lung parenchymal changes 
Of 125 patients without contiguous consolidation on the planning CT scan 14 (11%) 
developed contiguous consolidation during RT.  Of 125 patients with a pre-existing 
contiguous consolidation 30 (24%) had an increase and 4 (3%) a reduction. In total 44 of 250 
patients (18%) had a new or an increase in size of a contiguous consolidation during RT. 
Overall, 48 (19%) patients had changes in the lung parenchyma adjacent to the tumour not 
representing an alteration in tumour size. 
Of 132 patients without a non-contiguous consolidation on the planning CT scan 5 (4%) 
developed a non-contiguous consolidation during RT.  In 19 (16%) of 118 patients with a 
pre-existing non-contiguous consolidation there was an increase (11 in number of lesions 
and 8 in size of lesions) and in 2 a reduction in size during radiotherapy. In total 40 patients 
(16%) developed a new non-contiguous consolidation. 
Of 202 patients without pre-existing atelectasis on the planning CT scan 6 (3%) developed a 
new atelectasis during treatment. In 48 patients with a pre-existent atelectasis, 14 (29%) 
had an increase and 10 (21%) a decrease in atelectasis size. In total 20 patients (8%) 
developed a new atelectasis or increase in size of a pre-existing atelectasis during 
treatment. 
The median time interval between planning-CT and start of the treatment (first CBCT) was 
14 days (range 5–27 days). A significant correlation was found between longer time interval 
and development of changes (p = 0.011). There was no significant correlation found with 
patient characteristics, but there was a trend with advanced T stage and changes (p= 0.06).  
 
Changes within or adjacent to the treated tumour 
In 105 patients imaging changes were noted within or adjacent to the treated tumour; in 41 
(39%) patients these represented tumour enlargement while in 14 (13%) patients the 
changes were new and in 30 (29%) enlarging adjacent consolidation and in 20 (19%) new or 
enlarging atelectasis (Table 2). 
Timing and evolution of changes  
Enlargement of the primary lesion was noted almost exclusively at the first fraction (40 
patients out of 41). Most reductions were noted in the second half of treatment with a 
median time of onset in the third week of treatment.  Of 41 patients with tumour 
enlargement the lesion became smaller during treatment in 31, remained stable in 8 and 
progressed in 2. Of the total of 250 patients reduction in the size by the last week of 
treatment was noted in 126 (50%) patients. 
Changes adjacent to the tumour mass in the form of contiguous consolidation were noted at 
the first fraction in 29 (60%) patients and during the first week in 33 (69%), with further 6 in 
the second, 7 in the third and 2 on the fourth week of treatment. Of 44 patients with new or 
changed contiguous consolidation (enlarged pre-existing and new) in 20 patients this 
decreased in size over the course of treatment. 
The evolution of changes in non-contiguous consolidation and in atelectasis followed a 
similar pattern. Of 20 patients with enlarging and new atelectasis this fully or partially 
resolved in 9 patients over the course of treatment. 
Discussion 
CBCT is used primarily for adjustment of radiotherapy delivery to ensure accurate targeting 
of the tumour and optimal normal tissue avoidance 2. Identification and interpretation of 
the changes observed on CBCT is essential prior to altering treatment to ensure the 
adjustments made are appropriate. We report a systematic description and analysis of 
imaging abnormalities seen on CBCT and their evolution during and after radical RT in 
patients with locally advanced NSCLC. The CBCT images were treated as “diagnostic” scans 
using validated imaging descriptors in consultation with a thoracic radiologist. The aim was 
to improve the understanding of CBCT images and thereby improve the practice of image 
guided radiotherapy (IGRT) which may result in better treatment outcomes. The study did 
not focus on shifts and treatment adjustment although the interpretation of imaging 
changes has a direct implication for treatment delivery. 
Radiological changes on CBCT are common (observed in 72% of patients). Less than half 
(44%) represent changes in tumour size which may lead to adjustment to treatment 
delivery.  Just over half of the changes (56%) did not represent a change in tumour size. Of 
these two thirds were changes in abnormalities identified on planning CT and a third were 
abnormalities first noted during treatment. Intra-thoracic anatomical changes were 
reported on CBCT in 72% of patients treated with radiotherapy 4 with the purpose of 
defining changes that may need action (”Traffic Light Protocol”). These focussed principally 
on changes in tumour size and atelectasis though did not distinguish parenchymal changes 
adjacent to the tumour (contiguous consolidation) which may mimic alteration in tumour 
size and did not formally involve diagnostic imaging criteria. 
Identification of potential tumour enlargement during treatment is of particular relevance 
to IGRT in NSCLC 4-6. Missing a true enlargement not encompassed within the PTV may 
result in undertreatment while treatment adjustment to encompass apparent enlargement 
due to contiguous consolidation or atelectasis may lead to unnecessary treatment of normal 
tissues with a potential risk of increased toxicity. In the cohort studied increase in the size of 
the tumour and the adjacent opacities was noted in 85 patient and of these 41 represented 
increase in tumour size and 44 new or enlarged contiguous consolidation (Table 2). It can be 
concluded that more than half of the changes which suggest an apparent increase in tumour 
size are not due to tumour enlargement and therefore do not require adjustment to the 
target volume. 
Identification and correct interpretation of the evolution of imaging changes on CBCT during 
radiotherapy is of equal importance to the delivery of radiotherapy as parenchymal changes 
such as change in consolidation require different action than changes in tumour size.  
Increase in tumour size noted principally at the beginning of treatment is likely to reflect 
tumour growth in the period prior to commencing radiotherapy.  Tumours tend to decrease 
in size mostly towards the end of the treatment 4,5,7-14. Lung parenchymal changes also 
occur more frequently in the early stages of treatment and mostly tend to improve or 
resolve during the course of treatment (Appendix, Table III) 4,5,15,16. Our analysis of 
diagnostic imaging after treatment (Appendix, Table IVb) noted a continuing trend in 
reduction in the size of the tumour though a proportion remain stable.  
The complexity of evolution of lung parenchymal changes before (Appendix, Table I) and 
after RT (Appendix, Table IVa) suggests that the evolution of changes is affected by a 
number of factors related to disease, treatment and comorbidity (such as COPD).  
The current study does not provide information on the clinical significance of lung 
parenchymal changes - contiguous and non-contiguous consolidation (68) and new or 
enlarging atelectasis (20) (Table 2).  The majority of patients did not receive additional 
therapy such as antibiotics although this data was not comprehensively recorded. On the 
basis of the available information treatment with antibiotics for potential infective cause 
and the use of anticoagulants for thromboembolic disease should be principally guided by 
symptoms in the context of comorbidity (e.g. COPD) and appropriate diagnostic imaging 
rather than CBCT imaging abnormalities alone.  The management of imaging changes 
requires a separate prospective study. The issue of adaptive radiotherapy for reduction in 
tumour size (seen in 104 (42%) of patients (Table 2)) is currently open to debate and awaits 
results of prospective trials. 
CBCT images are subject to artefact and while the image quality continues to improve it 
does not yet reach the quality of diagnostic CT 17. In terms of the results reported here the 
presence of artefacts (not scored) may have resulted in some misreporting although the 
collaboration with and review by an experienced thoracic radiologist minimised such 
potential errors.  
We conclude that fast image analysis and interpretation of on-line or off-line CBCT is 
challenging and this may be compounded by the quality of CBCT images. The likelihood of 
misreporting in the clinical situation is therefore considerable and potentially greater than 
reported here. The data presented highlights the need for correct image interpretation 
which can be achieved by more detailed image inspection and analysis combined with 
appropriate training of personnel involved in lung IGRT.  The aim to improve accuracy of 
treatment delivery by adjustment based on CBCT should be a two step process. The first and 
critical step prior to adjustment requires “diagnostic” type image interpretation and this 
study provides information on the frequency of the observed changes only some of which 
require adjustment to treatment delivery.  
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APPENDIX 
Table I 
Abnormalities on planning CT scan and number of abnormalities per patient as absolute 
numbers and percentage in relation to total number of patients (250) and abnormalities 
(363). 
abnormalities on planning CT n abnormalities % patients 
% 
abnormalities 
contiguous consolidation 125 50% 34% 
non-contiguous consolidation 118 47% 33% 
cavitation 40 16% 11% 
effusion 32 13% 9% 
atelectasis 48 19% 13% 
Total changes 363 
 
100% 
    n abnormalities on planning CT n pts % patients 
 0 38 15% 
 1 106 42% 
 2 67 27% 
 3 33 13% 
 4 6 2% 
 Total 250 100% 
 any abnormality (1-4) 212 85% 
  
Table II 
Timing of changes during treatment as absolute numbers and percentage in relation to total 
number of changes (328), described by number of week of onset, onset on first fraction and 
median fraction. (cont cons: contiguous consolidation; dist cons: distant consolidation; 
pleural eff: pleural effusion) 
 
 
 
 
Table III 
total median
Change n % n % n % n % n % n n fraction
enlargement 40 98% 40 98% 1 2% 0 0% 0 0% 41 1
reduction 2 2% 7 7% 24 23% 42 40% 31 30% 104 14
cont cons 29 60% 33 69% 6 13% 7 15% 2 4% 48 1
dist cons 10 38% 15 58% 5 19% 2 8% 4 15% 26 4
cavitation 24 56% 27 63% 3 7% 4 9% 9 21% 43 1
pleural eff 13 36% 26 72% 6 17% 1 3% 3 8% 36 3
atelect 19 63% 20 67% 3 10% 4 13% 3 10% 30 1
TOT 137 42% 168 51% 48 15% 60 18% 52 16% 328 5
1st # 1st week 2nd week 3rd week 4th week
Evolution of changes on cone beam CT during treatment (comparing CBCT with CBCT) as 
absolute numbers and percentage in relation to number of changes of the same group. 
Lesion enlargement n % 
stable 8 20% 
increasing 1 2% 
reduction, then increase again 1 2% 
reduction to initial size 9 22% 
further reduction 22 54% 
Total 41 100% 
   Lesion reduction n % 
Stable or further reduction 104 100% 
   new contiguous consolidation n % 
persistent consolidation during RT (stable) 5 36% 
disappearance of consolidation 9 64% 
Total 14 100% 
   increased contiguous consolidation n % 
persistent increase during RT (stable) 19 63% 
reduction to initial size (as planning CT) 6 20% 
reduction to smaller size than planning CT 5 17% 
Total 30 100% 
   decreased contiguous consolidation n % 
stable 4 100% 
   new non-contiguous consolidation n % 
stable 5 100% 
  
  Increase in number of non-contiguous 
consolidation n % 
stable 8 73% 
slight reduction (still more compared to 
planning CT) 1 9% 
reduction as initial 2 18% 
Total 11 100% 
 
    
Increase in size of non-contiguous 
consolidation n % 
stable 4 50% 
reduction as initial 4 50% 
Total 8 100% 
  
 
  
Decrease in size of non-contiguous 
consolidation n % 
stable 1 50% 
increase 1 50% 
Total 2 100% 
   new cavitation n % 
stable 11 79% 
disappearance 3 21% 
Total 14 100% 
   increased cavitation n % 
stable 5 56% 
reduction as initial 2 22% 
further reduction 2 22% 
Total 9 100% 
   decresead cavitation n % 
stable 5 36% 
disappearance 6 43% 
increase to initial size 1 7% 
further increase 2 14% 
Total 14 100% 
   Disappearance of cavitation n % 
stable 2 33% 
reappearance but less than initial 1 17% 
reapparance bigger than initial 3 50% 
Total 6 100% 
   new pleural effusion n % 
stable 14 67% 
disappearance 6 29% 
reduction but still present 1 5% 
Total 21 100% 
   increased pleural effusion n % 
stable 8 80% 
reduction to initial size 2 20% 
Total 10 100% 
   decreased pleural effusion n % 
stable 2 67% 
more-less effusion 1 33% 
Total 3 100% 
   disappearance of effusion n % 
stable 2 100% 
   new atelectasis n % 
stable 4 67% 
disappearance 2 33% 
Total 6 100% 
   increased atelectasis n % 
stable 6 43% 
reduction to initial size 3 21% 
further reduction 4 29% 
reduction then increase 1 7% 
Total 14 100% 
   decreased atelectasis n % 
stable 10 100% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table IVa 
Evolution of changes after treatment (diagnostic CT scans after RT compared with CBCT 
during RT and planning CT scan) as absolute numbers and percentage in relation to number 
of changes of the same group. 
lesion enlargement n % 
progression 4 10% 
reduction 33 80% 
stable 2 5% 
no data 2 5% 
Total 41 100% 
   lesion reduction n % 
progression 4 4% 
further reduction 83 80% 
stable reduction 7 7% 
stable lesion 1 1% 
NA (consolidation) 3 3% 
no data 6 6% 
Total 104 100% 
   new contiguous consolidation n % 
increase in size of consolidation 5 36% 
stable consolidation 3 21% 
decrease in size of consolidation 2 14% 
disappearance of consolidation 4 29% 
Total 14 100% 
   increased contiguous consolidation n % 
further increase (>CBCT, >CT) 16 53% 
stable increase (=CBCT, >CT) 3 10% 
slight reduction (<CBCT, >CT) 2 7% 
reduction to initial (<CBCT, =CT) 3 10% 
further reduction (<CBCT, <CT) 3 10% 
disappearance of consolidation 1 3% 
no data 2 7% 
Total 30 100% 
   decreased contiguous 
consolidation n % 
further reduction (<CBCT, <CT) 1 25% 
slight increase (>CBCT, <CT) 1 25% 
further increase (>CBCT, >CT) 2 50% 
Total 4 100% 
   new non-contiguous consolidation n % 
stable consolidation 1 20% 
decrease in size of consolidation 1 20% 
decrease in number of consolidation 1 20% 
disappearance of consolidation 2 40% 
Total 5 100% 
   increased non-contiguous 
consolidation n % 
further increase (>CBCT, >CT) 5 26% 
stable increase (=CBCT, >CT) 7 37% 
slight reduction (<CBCT, >CT) 1 5% 
reduction to initial (<CBCT, =CT) 3 16% 
disappearance of all consolidations 2 11% 
no data 1 5% 
Total 19 100% 
   decreased non-contiguous 
consolidation n % 
further reduction (<CBCT, <CT) 1 50% 
increase (>CBCT, >CT) 1 50% 
Total 2 100% 
   new cavitation n % 
increase in size of cavitation 3 21% 
stable cavitation 1 7% 
decrease in size of cavitation 4 29% 
disappearance of cavitation 6 43% 
Total 14 100% 
   increased cavitation n % 
further increase (>CBCT, >CT) 2 22% 
stable increase (=CBCT, >CT) 1 11% 
reduction to initial (<CBCT, =CT) 1 11% 
further reduction (<CBCT, <CT) 2 22% 
disappearance of cavitation 2 22% 
no data 1 11% 
Total 9 100% 
   decreased cavitation n % 
disappearance of cavitation 7 50% 
stable reduction (=CBCT, <CT) 4 29% 
increase (>CBCT, >CT) 2 14% 
no data 1 7% 
Total 14 100% 
   
disappearance of cavitation n % 
stable (no cavity) 2 33% 
reapparance (<CT) 2 33% 
further increase (>CT) 1 17% 
no data 1 17% 
Total 6 100% 
   new pleural effusion n % 
increase in size of effusion 3 14% 
stable effusion 5 24% 
decrease in size of effusion 3 14% 
disappearance of effusion 10 48% 
Total 21 100% 
   increased pleural effusion n % 
further increase (>CBCT, >CT) 2 20% 
slight reduction (<CBCT, >CT) 3 30% 
reduction to initial (<CBCT, =CT) 2 20% 
further reduction (<CBCT, <CT) 2 20% 
disappearance of effusion 1 10% 
Total 10 100% 
   decreased pleural effusion n % 
further reduction (<CBCT, <CT) 2 67% 
disappearance of pleural effusion 1 33% 
Total 3 100% 
   disappearance of effusion n % 
stable (no effusion) 2 100% 
Total 2 100% 
   new atelectasis n % 
increase in size of atelectasis 1 17% 
stable atelectasis 1 17% 
decrease in size of atelectasis 1 17% 
disappearance of atelectasis 2 33% 
no data 1 17% 
Total 6 100% 
   increased atelectasis n % 
further increase (>CBCT, >CT) 3 21% 
stable increase (=CBCT, >CT) 2 14% 
slight reduction (<CBCT, >CT) 1 7% 
reduction to initial (<CBCT, =CT) 2 14% 
further reduction (<CBCT, <CT) 5 36% 
disappearance of atelectasis 1 7% 
Total 14 100% 
   decreased atelectasis n % 
further reduction 5 50% 
disappearance of atelectasis 1 10% 
stable reduction (=CBCT, <CT) 3 30% 
increase (>CBCT, >CT) 1 10% 
Total 10 100% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table IVb 
Evolution of tumour after treatment (comparing diagnostic CT scans after RT with CBCT 
during RT and planning CT scan) in patients who had no change in size of the tumour 
during RT (105) and in patients who had no radiological changes during RT (70),  as 
absolute numbers and percentage in relation to number of patients of the same group. 
no. change in size 
during RT n % 
progression 2 2% 
reduction 49 47% 
stable lesion 33 31% 
NA (consolidation) 10 10% 
no data 11 10% 
TOT 105 100% 
   no change n % 
progression 0 0% 
reduction 36 51% 
stable lesion 17 24% 
NA (consolidation) 6 9% 
no data 11 16% 
TOT 70 100% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
